Superworth

TherapeuticsMD EPS TXMD

Diluted earnings per share by quarter and over the last twelve months, from 2010.

Last 12 months, to Jun 30, 2026
−$0.02
Latest quarter, Q2 FY26
$0.01
−80% on a year earlier
Fiscal year 2025
−$0.05

TherapeuticsMD's earnings per share was −$0.02 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was $0.01, down 80% on the same quarter a year before.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$0.05n/a
FY2024−$0.18n/a
FY2023−$1.01−108%
FY2022$11.92n/a
FY2021−$21.70n/a
FY2020−$12.50n/a
FY2019−$35.50n/a
FY2018−$29.50n/a
FY2017−$19.00n/a
FY2016−$23.50n/a
FY2015−$25.00n/a
FY2014−$17.50n/a
FY2013−$11.50n/a
FY2012−$20.00n/a
FY2011−$9.00n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26$0.01−80%−$0.02
Q1 FY26$0.01n/a$0.02
Q4 FY25−$0.05−350%−$0.05
Q3 FY25$0.01n/a$0.02
Q2 FY25$0.05n/a−$0.04
Q1 FY25−$0.06n/a−$0.18
Q4 FY24$0.02n/a−$0.18
Q3 FY24−$0.05n/a−$0.28
Q2 FY24−$0.09n/a−$0.55
Q1 FY24−$0.06n/a−$0.70
Q4 FY23−$0.08−101%−$1.01
Q3 FY23−$0.32n/a$6.99

Against its peers

Companies in Drug Manufacturers - General nearest TherapeuticsMD's size, closest first, today.

CompanyEPS, 12 monthsGrowth
TXMDTherapeuticsMD−$0.02
ATNMActinium Pharmaceuticals$0.36
SPROSpero Therapeutics$0.11
LFVNLifevantage$0.40−46% a year
Peer median$0.36

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on TherapeuticsMD

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.